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Beneﬁt of Early Treatment in Inﬂammatory
Polyarthritis Patients With Anti–Cyclic
Citrullinated Peptide Antibodies Versus Those
Without Antibodies
TRACEY M. FARRAGHER,1 MARK LUNT,1 DARREN PLANT,1 DIANE K. BUNN,2 ANNE BARTON,1 AND
DEBORAH P. M. SYMMONS1
Objective. To compare the clinical utility of anti–cyclic citrullinated peptide (anti-CCP) antibodies and rheumatoid
factor (RF) testing in predicting both functional outcome and response to treatment in early inﬂammatory polyarthritis
(IP) patients.
Methods. A total of 916 IP subjects from a primary care incidence registry (1990–1994) had anti-CCP antibody and RF
status determined at baseline. Mean change in Health Assessment Questionnaire (HAQ) score between baseline and 5
years was compared by antibody status. The effect of treatment with disease-modifying antirheumatic drugs and/or
steroids over 5 years, early (<6 months of symptom onset) versus late initiation, and duration of treatment were also
compared by anti-CCP antibody status. The analysis was adjusted for treatment decisions and censoring over the
followup, using marginal structural models.
Results. Anti-CCP antibody–positive patients (n  268) had more severe disease both at presentation and 5 years of
followup, and this was independent of RF. On adjustment, anti-CCP antibody–negative patients treated early experienced
a signiﬁcant improvement in functional disability compared with anti-CCP antibody–negative patients who were never
treated (0.31; 95% conﬁdence interval [95% CI] 0.53, 0.08), and experienced additional beneﬁt for each additional
month of early treatment. Anti-CCP antibody–positive patients treated early did not have a signiﬁcant improvement in
HAQ score compared with those not treated (0.14; 95% CI 0.52, 0.24).
Conclusion. In this ﬁrst observational study to examine the inﬂuence of anti-CCP antibody status on treatment response,
anti-CCP antibody–positive IP patients showed less beneﬁt from treatment, particularly early treatment, than anti-CCP
antibody–negative patients. This provides support for the inclusion of anti-CCP antibodies as well as RF in the classiﬁ-
cation criteria for rheumatoid arthritis and for stratiﬁcation by anti-CCP antibody status in clinical trials.
INTRODUCTION
In the past few years, the potential role of anti–cyclic
citrullinated peptide (anti-CCP) antibodies has gained in-
creasing attention with respect to the diagnosis and clas-
siﬁcation of patients with inﬂammatory arthritis (1–3). In
recent systematic reviews and meta-analyses, anti-CCP
antibody positivity has been as sensitive as but more spe-
ciﬁc than rheumatoid factor (RF) for distinguishing rheu-
matoid arthritis (RA) from other forms of inﬂammatory
arthritis (1–3). Although there is an association between
the presence of RF and anti-CCP antibodies and the sub-
sequent development of RA (4,5), anti-CCP antibodies may
be detectable many years before RF and before the onset of
symptoms (6). Furthermore, anti-CCP antibody positivity
is associated with the development of erosions and radio-
logic progression (5–11), independent of the presence of
RF. Consequently, anti-CCP antibody–positive and anti-
CCP antibody–negative RA are increasingly viewed as sep-
arate disease entities (12). Most studies of the predictive
utility of anti-CCP antibodies have investigated either di-
agnosis or erosive damage, while few have evaluated its
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utility in clinical practice. In particular, very few studies
have compared the value of anti-CCP antibody and RF
status in predicting other long-term disease outcomes such
as functional disability (7,8), disease activity, and mortal-
ity (13).
The clinical utility of anti-CCP antibodies can also be
evaluated in terms of response to treatment. Early and
aggressive treatment of RA patients is clinically beneﬁcial
(14,15). Because anti-CCP antibodies are a marker of dis-
ease severity and are detectable early in the disease course,
they have the potential to identify those patients with
early inﬂammatory arthritis who will beneﬁt from treat-
ment. Disease severity is predictive of early diagnosis (16)
and can trigger the decision to treat. However, disease
severity is also predictive of poor treatment response (17);
thus, assessment of the differences in responses to treat-
ment by anti-CCP antibody status may be biased due to
confounding by indication. Therefore, although anti-CCP
antibodies might be a useful marker of who to treat, it is
not clear if they will predict those who respond best to
treatment.
The aim of this study was 1) to examine the association
of anti-CCP antibody and RF status with the long-term
outcome of patients with inﬂammatory polyarthritis (IP),
and 2) to examine the differences in response to treatment
by anti-CCP antibody status.
PATIENTS AND METHODS
The patients were recruited from the Norfolk Arthritis
Register (NOAR), a primary care–based inception cohort
of subjects with recent-onset IP. As described in detail
elsewhere (18), the NOAR aims to recruit all adults ages
16 years who have swelling of at least 2 joints persisting
for at least 4 weeks, and whose symptom onset was after
January 1, 1990. The NOAR catchment area covers the
former Norwich Health Authority, with notiﬁcation of
cases via general practitioners or hospital attendance.
Those who were subsequently diagnosed by a hospital
consultant as having a condition other than RA, IP, psori-
atic arthritis, or postviral arthritis were excluded. Between
1990 and 1994, 1,098 subjects who satisﬁed the above
criteria were registered with the NOAR. Of these, 913 sub-
jects had a blood sample collected at baseline permitting
serologic testing, and thus were included in this analysis.
Written consent was obtained from all of the patients
and the study was approved by the Norwich Local Re-
search Ethics Committee.
Data collection. Baseline. Clinical and demographic
data (Table 1) were collected by a research nurse via a
structured interview and clinical examination shortly after
registration (baseline). Detailed information was collected
on the use of disease-modifying antirheumatic drugs
(DMARDs) and steroids. Each subject completed the Health
Assessment Questionnaire (HAQ),modiﬁed for use in British
patients (19).
A blood sample was also taken for RF, anti-CCP anti-
body, and C-reactive protein (CRP) level testing. RF was
measured using a latex agglutination technique (positivity:
titer of 1:40). Anti-CCP antibodies were tested using the
Axis-Shield DIASTAT kit according to the manufacturer’s
instructions (positivity: concentration 5 units/ml). CRP
levels (mg/liter) were measured using an end-point immu-
noturbidimetric agglutination method. The Disease Activ-
ity Score in 28 joints (DAS28) was calculated using CRP
level and 28 tender and 28 swollen joint counts (online at:
http://www.das-score.nl/www.das-score.nl/index.html).
Followup. Annual assessments were carried out for 3
years, and then at the ﬁfth year. Dates of starting and
stopping any DMARD therapy were recorded. A blood
sample was taken from all of the subjects at the ﬁfth
assessment for RF and CRP level testing. The American
College of Rheumatology (ACR; formerly the American
Rheumatism Association) 1987 classiﬁcation criteria for
RA (20) were applied both cross-sectionally at baseline
and cumulatively at each subsequent assessment (21).
Patients attended for radiographs of their hands and feet
at the ﬁrst and/or second assessments if they had already
satisﬁed the ACR criteria for RA or if the presence of
erosions would lead to their satisfying these criteria. All of
the patients were invited for radiographs at the 5-year
followup. Radiographs were scored using the Larsen
method (22) by 2 rheumatologists and major disagree-
ments were arbitrated by a third (23). The patients com-
pleted the Medical Outcomes Study Short Form 36 (24), a
validated generic health status measure, at the third and/or
ﬁfth years (25).
Where relevant, the Ofﬁce for National Statistics pro-
vided details of the patients’ deaths, including the cause
and date of death. In the analysis, each patient was fol-
lowed from the date of baseline assessment until death or
5 years from baseline, whichever was sooner.
Statistical analysis. The patients were placed into 1 of 4
autoantibody groups, determined by serologic assessment
of baseline serum: anti-CCP antibody negative/RF nega-
tive, anti-CCP antibody negative/RF positive, anti-CCP
antibody positive/RF negative, or anti-CCP antibody posi-
tive/RF positive. Differences in the patient characteristics
at baseline between (i.e., all 4 groups) and within (e.g.,
anti-CCP antibody–negative subjects by RF status) the
autoantibody groups were tested using regression models.
Depending on the outcome being tested, the following
models were used: median regression for continuous non-
normal outcomes, logistic regression for binary outcomes,
negative binomial regression for counts, and multinomial
logistic regression for categorical outcomes. Furthermore,
the differences in patient characteristics at baseline be-
tween anti-CCP antibody–positive/–negative patients were
tested using the following: the Kruskal-Wallis test for con-
tinuous outcomes and the chi-square test for categorical
outcomes. The differences in outcomes by 5 years between
anti-CCP antibody–positive/–negative patients were inves-
tigated (linear regression for changes in continuous out-
comes [adjusted by baseline] and logistic regression for the
odds of categorical outcomes by 5 years).
Treatment history. To assess the impact of treatment,
particularly early treatment, by anti-CCP antibody status
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on 5-year outcome, the change in HAQ model was then
stratiﬁed by treatment history. The time from disease
symptom onset to the date of ﬁrst treatment (any
DMARDs/steroids) was categorized as early (6 months)
or late (6 months). The duration of any DMARD/steroid
treatment, including combination therapies, was stratiﬁed
into the number of months of treatment in the ﬁrst 6
months since symptom onset and the number of months of
treatment after the ﬁrst 6 months since symptom onset.
Marginal structural models. We have previously used a
propensity score (26) to adjust for “confounding by indi-
cation.” However, propensity methods assume a single
treatment decision made at a predetermined point in time,
whereas in practice, treatment is likely to change in re-
sponse to changes in disease severity. These changes in
severity may also affect the HAQ score at the end of 5
years, so if we do not take them into account, we will get
a biased estimate of the effect of treatment.
Table 1. Variables used in the marginal structural weight models*
Variable Variable type
Demographics
Age at symptom onset and at each assessment Decades
Sex Male
Female
Months from symptom onset at baseline and at each assessment Tertiles by assessment
Smoking status at each assessment Never smoked
Stopped 10 years prior to assessment
Stopped 10 years prior to assessment
Current smoker
Serologic and genetic
Anti-CCP antibody status at baseline (Axis-Shield DIASTAT kit) 5 units/ml
5 units/ml
CRP level category at baseline and assessment (end-point immunoturbidimetric
agglutination)
10 mg/liter
10 mg/liter
RF status at baseline and assessment (latex agglutination) 1:40
1:40
Number of copies of the shared epitope 0
1
2
Homozygous for the shared epitope No
Yes
Disease activity and severity
DAS28 score at baseline and assessment
ACR criteria for RA, cross-sectional at baseline and cumulative at assessment Not met
Met
Number of swollen, tender, and both swollen and tender joints at baseline and
assessment
Tertiles by assessment
Presence of nodules at baseline and assessment No
Yes
HAQ score group at baseline and assessment 1
1 to 2
2
Presence of erosions by assessment No
Yes
Larsen score by assessment Tertiles by assessment
Physical component score of the SF-36
Mental component score of the SF-36
Diagnosed with any of 14 deﬁned comorbidities by assessment No
Yes
Treatment and hospital attendance
Attended/referred to hospital since last assessment No
Yes
Treated with SSZ, MTX, other DMARDs, and steroids at baseline and by
assessment
No
Yes
Ceased treatment since last assessment or by assessment due to inefﬁcacy or
adverse event
No
Yes
Remission by baseline and assessment No
Yes
* Anti-CCP anti–cyclic citrullinated peptide; CRP C-reactive protein; RF rheumatoid factor; DAS28 Disease Activity Score in 28 joints; ACR
American College of Rheumatology; RA  rheumatoid arthritis; HAQ  Health Assessment Questionnaire; SF-36  Medical Outcomes Study Short
Form 36; SSZ  sulfasalazine; MTX  methotrexate; DMARDs  disease-modifying antirheumatic drugs.
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However, we cannot use conventional regression adjust-
ment, since the changes in disease severity will be affected
by the previous treatments received. If we include inter-
mediate HAQ scores, for example, in a regression model,
we will adjust away part of the effect of treatment and
again end up with a biased estimate.
The alternative to regression adjustment for confound-
ing is to use weighting (27). If we consider ﬁrst the simple
case of a single treatment decision, we can assign weights
to individuals so that the distributions of all confounding
variables are the same in the treated and untreated sub-
jects. For example, if the HAQ score tended to be higher in
the treated subjects than in the untreated subjects, we
could up-weight untreated subjects with high HAQ scores
and down-weight untreated subjects with low HAQ scores,
until the distribution of HAQ scores in the untreated sub-
jects was the same as that in the treated subjects, and the
HAQ score would no longer be a confounder. In practice,
we would want to equalize the distributions of a number of
variables, and this can be done by including all of the
variables in a logistic regression model to predict the prob-
ability of treatment: if we weight to balance the probabil-
ities of treatment between treated and untreated subjects,
we will balance all of the variables that make up the
propensity score, and therefore none of them will con-
found the association between treatment and outcome. If
the predicted probability of treatment for the ith subject is
pi, then the appropriate weights to use are 1/pi for treated
subjects and 1/(1  pi) for untreated subjects; these are
referred to as inverse probability of treatment weights
(IPTW) (28). To allow for time-varying confounding, we
can calculate weights each time that a treatment decision
is made. Weighting individuals by the product of these
time-speciﬁc weights will eliminate confounding by the
history of confounders; the resulting model is referred to
as a marginal structural model (29–32).
A similar weighting approach (inverse probability of
censoring weight [IPCW]) can be used to remove the bias
due to loss to followup. Weighting by the product of the
IPTW and IPCW produces a population in which both
treatment and loss to followup are independent of any of
the variables considered potential time-varying confound-
ers, enabling an unbiased estimate of the effect of treat-
ment to be obtained.
Potential confounders are listed in Table 1. At each
assessment, we included the values of all of these variables
at the current assessment, at baseline (if different from the
current assessment), and at the previous assessment (if
different from the current assessment and baseline) into a
logistic regression model. The outcome in this model was
1 if the subject was receiving treatment at that assessment,
and 0 if not. The product of the assessment-speciﬁc
weights produces an individual’s IPTW. The same vari-
ables and methodology were used to calculate the IPCW,
the only difference being that the outcome was 1 if the
subject was censored before the next assessment.
We also had to consider the problem of missing data,
since excluding subjects with missing data can lead to
biased estimates (33), as well as reducing statistical efﬁ-
ciency. We imputed missing data using switching regres-
sion, an iterative multivariable regression technique that
retains an element of random variation in the estimates
(34). Within Stata, these methods were incorporated
within the ice and uvis programs (35). All analyses were
undertaken using Stata, version 9.2.
RESULTS
Associations between autoantibodies and patient char-
acteristics at baseline assessment. At baseline, 268
(29.3%) of the 916 subjects were anti-CCP antibody posi-
tive and 255 (27.8%) were RF positive (Table 2). There
were signiﬁcant differences in the majority of baseline
characteristics between the 4 autoantibody groups. How-
ever, the differences in disease activity and severity appear
to be restricted to anti-CCP antibody status, irrespective of
RF status. Anti-CCP antibody–positive patients had the
highest DAS28 scores, irrespective of whether they were
RF negative or RF positive (difference in DAS28 0.13;
95% conﬁdence interval [95% CI] 0.59, 0.33). However,
signiﬁcantly more patients satisﬁed the ACR criteria for RA if
they were RF positive and anti-CCP antibody negative than if
they were RF negative and anti-CCP antibody negative (dif-
ference 23.6%; 95% CI 11.1, 36.2), probably reﬂecting that
RF is part of the ACR criteria for the classiﬁcation of RA.
The differences in 5-year clinical characteristics were
also explained by anti-CCP antibodies rather than RF sta-
tus (data not shown); therefore, all subsequent analysis
focused on anti-CCP antibody status only. Patients who
were anti-CCP antibody positive at baseline were more
likely to be older, male, satisfy ACR criteria for RA, and
have more severe disease, including the presence of ero-
sions, compared with those who were anti-CCP antibody
negative at baseline (Table 3). In keeping with previous
reports, anti-CCP antibody–positive patients were more
likely to have smoked (P  0.001).
Differences in treatment over 5 years by anti-CCP anti-
body status. Patients who were anti-CCP antibody posi-
tive at baseline were more likely to have been treated with
DMARDs/steroids by 5 years than those without anti-CCP
antibodies (85.4% versus 37.5%; P  0.001) (Table 4).
Over the 5 years of followup, anti-CCP antibody–positive
patients who received treatment were more likely to re-
ceive sulfasalazine (SSZ; P  0.001), methotrexate (MTX;
P  0.001), or other DMARDs (P  0.001), whereas anti-
CCP antibody–negative patients who received treatment
were more likely to receive steroids (P  0.001). As the
anti-CCP antibody status of the patients was unknown at
the time of treatment, these differences reﬂect anti-CCP
antibody status as a marker of disease severity. There were
no differences in the time to and on ﬁrst treatment by
anti-CCP antibody status. However, anti-CCP antibody–
positive patients were receiving treatment for a longer
period of time over the followup (P  0.001).
Associations between anti-CCP antibodies and out-
comes by 5 years of followup and differences in treatment
response. All 5-year disease outcomes were worse in pa-
tients who were anti-CCP antibody positive at baseline
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Table 3. Baseline characteristics of cohort by anti-CCP antibody status*
All IP patients IP patients assessed at 5 years
Anti-CCP
antibody
negative
(n  648)
Anti-CCP
antibody
positive
(n  268) P
Anti-CCP
antibody
negative
(n  515)
Anti-CCP
antibody
positive
(n  214) P
Age at symptom onset, years† 52 (39–66) 56 (48–66)  0.001 51 (40–64) 55.5 (47–64) 0.002
Women, no. (%)‡ 431 (66.5) 152 (56.7) 0.005 356 (69.1) 129 (60.3) 0.023
Symptom duration at
registration, months†
4 (2–10) 5 (2–10.5) 0.23 4 (2–10) 5 (2–10) 0.55
HAQ score (n  910)† 0.625 (0.25–1.25) 0.88 (0.375–1.625)  0.001 0.625 (0.25–1.25) 0.875 (0.375–1.625) 0.003
CRP level, mg/liter (n  845)† 3 (0–11) 12 (4–31)  0.001 3 (0–10) 10 (3–23)  0.001
DAS28 score (n  845)† 3.73 (2.66–4.8) 4.4 (3.4–5.45)  0.001 3.76 (2.78–4.82) 4.41 (3.43–5.37)  0.001
Swollen joint count† 6 (2–12) 8 (4–16.5)  0.001 6 (2–12) 8 (4–16)  0.001
Tender joint count† 7 (2–16) 8 (4–16) 0.17 7 (2–17) 8 (4–16) 0.29
Swollen and tender joint count† 3 (0–8) 4 (1–9) 0.002 3 (0–8) 4 (1–9) 0.006
Satisfy ACR criteria for RA, no.
(%)‡
241 (37.2) 194 (72.4)  0.001 203 (39.4) 155 (72.4)  0.001
Smoking status at baseline, no.
(%)‡
0.001 0.025
Never smoked 221 (34.3) 69 (25.8) 180 (35.2) 60 (28)
Ex-smoker for 10 years 177 (27.5) 56 (21) 141 (27.6) 48 (22.4)
Ex-smoker for 10 years 90 (14.0) 55 (20.6) 70 (13.7) 42 (19.6)
Current smoker 156 (24.2) 87 (32.6) 120 (23.5) 64 (29.9)
* Values are the median (interquartile range) unless otherwise indicated. Anti-CCP  anti–cyclic citrullinated peptide; IP  inﬂammatory polyar-
thritis; HAQ  Health Assessment Questionnaire; CRP  C-reactive protein; DAS28  Disease Activity Score in 28 joints; ACR  American College
of Rheumatology; RA  rheumatoid arthritis.
† Kruskal-Wallis test was used to test signiﬁcance between the groups.
‡ Chi-square test was used to test signiﬁcance between the groups.
Table 4. Treatment characteristics over 5 years of followup by anti-CCP antibody status*
Anti-CCP
antibody negative
(n  648)
Anti-CCP
antibody positive
(n  268)
Treated with DMARDs/steroids over 5 years
No 405 (62.5) 39 (14.6)
Yes 243 (37.5) 229 (85.4)
Treatment ever over 5 years†
Sulfasalazine 128 (52.7) 173 (75.5)
Methotrexate 63 (25.9) 110 (48.0)
Steroids 104 (42.8) 83 (36.2)
Other DMARDs 29 (11.9) 33 (14.4)
First treatment type†
Sulfasalazine 119 (49.0) 161 (70.3)
Methotrexate 32 (13.2) 28 (12.2)
Steroids 90 (37.0) 46 (20.1)
Other DMARDs 20 (8.2) 20 (8.7)
Response to ﬁrst treatment over 5 years†
Still on 49 (20.2) 41 (17.9)
Changed combination 136 (56.0) 93 (40.6)
Stopped 47 (19.3) 93 (40.6)
Time to ﬁrst treatment, median (IQR) months 6 (2–18) 7 (4–15)
Time on ﬁrst treatment, median (IQR) months 21 (6–54) 20 (5–49)
Time on any treatment over 5 years, median (IQR) months 50.5 (20.5–61) 58 (39–62)
* Values are the number (percentage) unless otherwise indicated. Anti-CCP  anti–cyclic citrullinated peptide; DMARDs 
disease-modifying antirheumatic drugs; IQR  interquartile range.
† Percentages are of those treated.
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both in absolute value and in change from baseline
(Table 5). As with baseline characteristics, these differ-
ences were independent of RF status (data not shown).
Anti-CCP antibody–positive patients experienced a signif-
icant increase in HAQ score over the 5 years (mean change
0.20; 95% CI 0.09, 0.31), whereas anti-CCP antibody–
negative patients experienced no change in HAQ score
(mean 0.005; 95% CI 0.06, 0.07).
Signiﬁcant differences in the disease outcomes in anti-
CCP antibody–positive/–negative patients remained fol-
lowing adjustment for baseline value, age at onset, and sex
(Table 5). Anti-CCP antibody–positive patients had signif-
icantly worse outcomes in HAQ scores, joint counts, and
DAS28 scores, had higher odds of erosions, and were more
likely to satisfy the ACR criteria for RA by 5 years than
anti-CCP antibody–negative patients.
Anti-CCP antibody–positive patients beneﬁted less from
treatment, particularly early treatment, than anti-CCP
antibody–negative patients in terms of functional disabil-
ity (Table 6). Compared with anti-CCP antibody–negative
patients who were never treated, anti-CCP antibody–nega-
tive patients who were treated early experienced a signif-
icant improvement in functional disability by 5 years, after
allowing for treatment history and censoring over the fol-
lowup (mean adjusted difference in change in HAQ score
0.31; 95% CI 0.53, 0.09). Furthermore, anti-CCP
antibody–negative patients treated within the ﬁrst 6
months experienced a signiﬁcant improvement in HAQ
score compared with those treated later (mean adjusted
difference in change 0.52; 95% CI 0.89, 0.14). There
was no signiﬁcant change in HAQ score in anti-CCP anti-
body–positive patients treated early compared with those
anti-CCP antibody–positive patients never treated (0.14;
95% CI 0.52, 0.24). There was also a nonsigniﬁcant im-
provement in HAQ score in those anti-CCP antibody–posi-
tive patients treated within the ﬁrst 6 months compared
with those treated later (0.25; 95% CI 0.62, 0.11). Anti-
CCP antibody–negative patients experienced signiﬁcant
additional beneﬁt for each additional month of early treat-
ment (0.13; 95% CI 0.22, 0.04), whereas anti-CCP
antibody–positive patients did not (0.05; 95% CI 0.18,
0.07).
DISCUSSION
In this primary care–based inception cohort of patients
with recent-onset IP, we found an association between the
presence of anti-CCP antibodies at baseline and more se-
vere disease both early in the disease and at 5 years of
followup, and this association was independent of RF. As
a marker of disease severity, anti-CCP antibodies not only
Table 5. Five-year outcomes by anti-CCP antibody status*
5-year outcome
Anti-CCP
antibody negative
(n  515)
Anti-CCP
antibody positive
(n  214)
Anti-CCP antibody
positive vs. anti-CCP
antibody negative
(adjusted by baseline)
HAQ score, median (IQR) 0.625 (0–1.375) 1.13 (0.5–1.875)
Change in HAQ score, mean (95% CI)† 0.005 (0.06, 0.07) 0.20 (0.09, 0.31)
Mean difference (95% CI) 0.27 (0.16, 0.39)
Swollen joint count, median (IQR) 0 (0–2) 3 (0–6.5)
Change in swollen joint count since baseline,
mean (95% CI)‡
7 (8, 6) 6 (7, 4)
Mean difference (95% CI) 2.79 (1.98, 3.6)
Tender joint count, median (IQR) 1 (0–6) 2 (0–9.5)
Change in tender joint count since baseline,
mean (95% CI)‡
7 (8, 5) 4 (6, 2)
Mean difference (95% CI) 2.54 (0.96, 4.12)
Swollen and tender joint count, median (IQR) 0 (0–1) 1 (0–4)
Change in swollen and tender joint count
since baseline, mean (95% CI)‡
4 (5, 4) 3 (4, 1)
Mean difference (95% CI) 2.07 (1.35, 2.79)
DAS28 score, median (IQR) 2.22 (1.42–3.09) 3.09 (2.17–4.23)
Change in DAS28 score, mean (95% CI)§ 1.33 (1.49, 1.17) 0.92 (1.25, 0.6)
Mean difference (95% CI) 0.78 (0.52, 1.05)
Satisfy ACR criteria cumulatively for RA, no.
(%)¶
317 (61.6) 205 (95.8)
OR (95% CI) 14.23 (7.13, 28.39)
Presence of erosions, no. (%)# 135 (29.4) 162 (80.6)
OR (95% CI) 9.97 (6.66, 14.92)
* Anti-CCP  anti–cyclic citrullinated peptide; HAQ  Health Assessment Questionnaire; IQR  interquartile range; 95% CI  95% conﬁdence
interval; DAS28  Disease Activity Score in 28 joints; ACR  American College of Rheumatology; RA  rheumatoid arthritis; OR  odds ratio.
† Linear regression was used to compare outcomes between the groups. The HAQ was completed at baseline and 5 years by 710 subjects.
‡ Linear regression was used to compare outcomes between the groups. Joints were examined at baseline and 5 years on 528 subjects.
§ Linear regression was used to compare outcomes between the groups. The DAS28 score was calculated at baseline and 5 years for 419 subjects.
¶ Logistic regression was used to compare outcomes between the groups.
# Logistic regression was used to compare outcomes between the groups. Radiographs were examined at baseline and 5 years on 660 subjects.
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predict disease outcomes but also the treatment given over
the 5 years. To our knowledge, this is the ﬁrst observa-
tional study to examine the inﬂuence of anti-CCP antibody
status on treatment response as assessed by change in
functional disability. We found that anti-CCP antibody–
positive patients with IP showed less beneﬁt from treat-
ment, particularly early treatment, than anti-CCP anti-
body–negative patients.
Several studies have shown the predictive value of anti-
CCP antibodies for radiographic progression (5–11), al-
though the independent role of the antibody in compari-
son with RF has not yet been conﬁrmed. Some
investigators showed that both RF and anti-CCP antibodies
are independent predictors (6,7,10,11), whereas others
have shown that anti-CCP antibodies rather than RF are
the independent predictor of radiographic progression (9),
in particular in those patients who were seronegative for
RF (8,36). The predictive value of anti-CCP antibodies in
seronegative patients was also seen in terms of functional
disability (8), although RF rather than anti-CCP antibodies
was a predictor of functional disability in a multiple re-
gression model (7). These contradictory results may be a
result of studying patients with different durations of dis-
ease. The presence of anti-CCP antibodies precedes RF,
and indeed, anti-CCP antibodies may be found many years
before disease onset (37). In our analysis of patients with
early IP, we found that at baseline and 5 years, all of the
disease outcome measures were differentiated by anti-CCP
antibody status rather than RF at baseline. In particular, in
RF-negative patients, the disease outcomes were worse for
those with anti-CCP antibodies than those without at base-
line. This provides evidence that the marker of disease
severity early in the disease process is anti-CCP antibodies
rather than RF. Furthermore, the restriction of some stud-
ies to patients who satisfy the ACR criteria for RA early in
the disease course might have masked the predictive role
of anti-CCP antibodies in comparison with RF, as the latter
forms part of the criteria for the classiﬁcation of RA. We
have previously shown that anti-CCP antibodies are asso-
ciated with premature mortality (38). The only other study
to compare the association of mortality and anti-CCP an-
tibodies found in a cross-sectional cohort of established
RA patients that RF, but not anti-CCP antibodies, was
associated with mortality (13). However, high anti-CCP
antibody titers were associated with mortality in that co-
hort.
Further evidence that anti-CCP antibodies are a marker
of disease severity is provided by the differences in treat-
ments given over the 5 years by anti-CCP antibody status at
baseline. At the time of treatment, the anti-CCP antibody
status was unknown and thus cannot have directly inﬂu-
enced treatment decisions. Nevertheless, anti-CCP anti-
body–positive patients were more likely to be prescribed
SSZ, whereas anti-CCP antibody–negative patients were
more likely to have been prescribed steroids. In a longitu-
dinal study, Ro¨nnelid et al found no difference in the
proportion of patients initially treated with DMARDs by
anti-CCP antibody status (39). However, patients who were
positive for anti-CCP antibodies were treated longer with
SSZ or combination therapy, whereas anti-CCP antibody–
negative patients were more often treated with auranoﬁn.
In a recent-onset RA cohort, DMARD treatment was more
often started in patients positive for anti-CCP antibodies
and antimalarials were more likely to be given to anti-CCP
antibody–negative patients (40). These differences in treat-
ment given might account for the differences in the re-
sponse to treatment we have seen. However, after adjust-
ing for disease severity over the followup, we found that
those patients negative for anti-CCP antibodies showed
more beneﬁt from treatment, particularly early treatment.
Furthermore, we did not ﬁnd a signiﬁcant difference in the
change in HAQ score between those ever treated with
MTX and SSZ using the marginal structural model, indi-
cating that this model was successful in accounting for
differences in treatments (data not shown).
Because our cohort was recruited and followed in the
prebiologics era, the comparison of treatment response is
for traditional DMARDs, and we cannot comment on the
inﬂuence of anti-CCP antibody status in response to bio-
logics. It is unclear if treatment (either traditional
DMARDs or anti–tumor necrosis factor [anti-TNF] ther-
apy) alters anti-CCP antibody levels. Some studies have
shown that DMARDs (40) and anti-TNF therapies (41–44)
reduce anti-CCP antibody titers, whereas others have
shown no change in anti-CCP antibody titers but a reduc-
tion in RF titers (45–47). Other studies have shown that
anti-CCP antibody positivity or titer predicts poor re-
sponse to anti-TNF treatment (48–51). Our study conﬁrms
this association in functional disability, while adjusting
for the disease severity marked by anti-CCP antibodies. In
a randomized trial comparing 4 targeted treatment strate-
gies, anti-CCP antibody and RF status only predicted pro-
gressive disease in the sequential monotherapy group and
not the combination therapy groups (52), suggesting that
anti-CCP antibodies are not a universal predictor of poor
treatment response. Taken together with these previous
studies, our work shows that anti-CCP antibody–negative
patients do beneﬁt from treatment such as steroids and
monotherapy, whereas anti-CCP antibody–positive pa-
tients require more aggressive therapies. Furthermore,
clinical trials in RA and IP should stratify for anti-CCP
antibody status.
This study used a primary care–based cohort of subjects
with IP, and therefore had limited selection bias. The
strength of studying all IP cases rather than only those
subjects classiﬁed as RA is that we will have included
subjects with milder disease and provided a valuable in-
sight into treatment response in this group. There was a
relatively high proportion of patients with neither auto-
antibody at baseline. It is recognized that patients may
seroconvert over the subsequent years, particularly with
regard to RF, and thus there may have been some misclas-
siﬁcation. However, our study shows that early in the
disease course, anti-CCP antibody status predicts disease
outcome and treatment response in the long term. Further-
more, the association between features at baseline and
anti-CCP antibody rather than RF status was also seen at 5
years. The use of IP subjects could explain why anti-CCP
antibody–negative patients have better outcomes, even on
adjustment for disease activity, due to a combination of
self-limited disease and whether they progress to develop
RA. However, this is unlikely to be the case, and restricting
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the analysis shown in Table 6 to those who met ACR
criteria for RA by 5 years gave the same results as using all
IP subjects (data not shown).
Adjusting for a series of treatment decisions and ﬂuctu-
ating disease activity over 5 years is complex, and a variety
of methods have been suggested, including propensity
scores (53), as we have used previously (26,54). Here we
have used marginal structural models because they are the
only method that adjusts for time-varying confounders.
There is a debate as to which variables should be included
in the models to estimate the weights (55). Rubin (56) and
Robins et al (57) recommend the inclusion of variables
even with weak effects on outcome (although strong asso-
ciations with treatment) in order to minimize bias. Results
from simulation experiments (55) suggest that variables
related to outcome but not to treatment should always be
included because they decrease the variance of estimates
without increasing bias, i.e., overﬁtting is a positive aspect
of these models. However, the possibility of residual con-
founding remains due to unmeasured variables that are
associated either with treatment decisions or with out-
come. Although we included variables that cover the full
spectrum of disease activity, previous treatment, and co-
morbidity, unmeasured confounders might include pa-
tient preferences and compliance. We were able to test
(Hosmer-Lemeshow goodness-of-ﬁt test) if the models
used to estimate the weights were successful in predicting
changes in both treatment and loss to followup, and the
IPTW and IPCW models were very successful (P  0.81
and P  0.82, respectively).
Consideration is also required of the number of variables
included in the models used to produce the weights and in
what form they were included. The recommended sample
size is between 200 and 400 subjects or 10–20 cases for
each variable included (58,59). Therefore, we had ade-
quate power to use marginal structural models in this
context, i.e., 916 subjects with 23 variables. Because the
weights produced from the models rather than the esti-
mates directly were used, the variables are included based
on how the clinician would use that information in their
decision rather than on the efﬁciency of any estimates.
Does this mean that anti-CCP antibody testing should
replace RF in routine clinical practice? From this work, it
would appear that their use in conjunction should remain
(60). Our study provides further evidence for the reevalu-
ation of the 1987 classiﬁcation criteria for RA, and support
for including anti-CCP antibody status as well as RF status.
Anti-CCP antibody–negative patients beneﬁt from mono-
therapy, whereas anti-CCP antibody–positive patients re-
quire more aggressive therapy.
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